BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24999662)

  • 1. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
    Morzaria S; Damrose EJ
    J Laryngol Otol; 2011 Jul; 125(7):714-8. PubMed ID: 21524329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
    Lee SJ; Kang MS; Choi HS; Lim JY
    Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
    Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
    Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
    Novakovic D; Waters HH; D'Elia JB; Blitzer A
    Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulcus vocalis in spasmodic dysphonia-A retrospective study.
    Nerurkar NK; Agrawal D; Joshi D
    Am J Otolaryngol; 2021; 42(3):102940. PubMed ID: 33545449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current practices in the management of adductor spasmodic dysphonia.
    Eskander A; Fung K; McBride S; Hogikyan N
    J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
    French G; Bosch JD; Randall DR
    J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
    Chang CY; Chabot P; Walz CM
    Ear Nose Throat J; 2009 May; 88(5):E18. PubMed ID: 19444777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.